OPULUS
Welcome Guest (Log in, Subscribe
 What's New | Home | About Us | Contact Us | Help Center | Publications | Site Map | Links | Subscription 


Last update:2012.04.04.
 Regulatory Basis  Forum Issues  Intelligence Services  Web Applications  21 CFR Part 11 Compliant Products 

Search: 
Intelligence Services
Endotoxin
OOS
21 CFR Part 11
Dissolution
Competency Training
Blend Uniformity
Validation
Patent databases


Adobe Acrobat Reader
Where are you now? Intelligence Services > Dissolution > Related Regulations

Dissolution Regulations

These files are in Adobe PDF format.
Click on the "Get Acrobat Reader" icon on the left of the page to
download a free copy of the Acrobat Reader.

sort by
Title
sort by
  Date  
 Download 

Levothyroxine Sodium Tablets - In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing
This guide is intended to assist sponsors of new drug applications (NDAs) for levothyroxine sodium tablets who wish to conduct in vivo harmacokinetic and bioavailability studies and in vitro dissolution testing of their products, FDA

 2000-12-01   PDF PDF file (30 KB) 

Average, Population, and Individual Approaches to Establishing Bioequivalence
This guide provides recommendations to sponsors of investigational new drug applications (INDs), new drug applications (NDAs), and abbreviated new drug applications (ANDAs) who intend, either before or after approval, to perform in vivo or in vitro bioequivalence (BE) studies, FDA

 1999-08-01   PDF PDF file (325 KB) 

Quality of Modified Release Products: A: Oral Dosage Forms B: Transdermal Dosage Forms, Section I (Quality)
This Note for Guidance concerns quality aspects, especially, in vitro testing, of dosage forms in which release of active substance is modified. EMEA

 1999-07-01   PDF PDF file (74 KB) 

Topical Dermatological Drug Product NDAs and ANDAs - In Vivo Bioavailability, Bioequivalence, In Vitro Release, and Associated Studies
This guide provides recommendations to sponsors and applicants who intend to provide, during either the pre- or postapproval period, information on bioavailability (BA) and bioequivalence (BE), and chemistry, manufacturing and controls in support of a new drug application (NDA), an abbreviated new drug application (ANDA), or a supplement for topical dermatological drug products.

 1999-06-01   PDF PDF file (117 KB) 

Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action
This guide is intended to provide recommendations to applicants who are planning product quality studies to measure bioavailability (BA) and/or establish (BE) in support of new drug applications (NDAs) or abbreviated new drug applications (ANDAs) for locally acting drugs in nasal aerosols (metered-dose inhalers (MDIs)) and nasal sprays (metered-dose spray pumps), FDA

 1999-06-01   PDF PDF file (113 KB) 

Dissolution Testing of Immediate Release Solid Oral Dosage Forms
This guide has been developed for immediate release (IR) dosage forms and is intended to provide (1) general recommendations for dissolution testing; (2) approaches for setting dissolution specifications related to the biopharmaceutic characteristics of a drug substance; (3) statistical methods for comparing dissolution profiles; and (4) a process to help determine when dissolution testing is sufficient to grant a waiver for an in vivo bioequivalence study, FDA

 1999-06-01   PDF PDF file (116 KB) 

Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Containing Certain Active Moieties/Active Ingredients Based on a Biopharmaceutics Classification System
The purpose of this guide is to describe alternative methods, not based on in vivo methods, that are acceptable to FDA for demonstrating bioequivalence for certain post-1962 immediate release solid oral drug products based on a classification system that distinguishes rapidly dissolving drug products containing active moieties/active ingredients that are highly soluble and highly permeable from other drug products.

 1999-01-01   PDF PDF file (41 KB) 

The Investigation of Bioavailability and Bioequivalence
The objective of this guide to define, for products with a systemic effect, when bioavailability or bioequivalence studies are necessary and to formulate requirements for their design, conduct, and evaluation.

 1998-12-01   PDF PDF file (84 KB) 

SUPAC-IR/MR: Immediate Release and Modified Release Solid Oral Dosage Forms Manufacturing Equipment Addendum
This guide provides recommendations to pharmaceutical manufacturers using the Center for Drug Evaluation and Research's Guidance for Industry: Immediate Release Solid Oral Dosage Forms - Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (SUPAC-IR)

 1998-04-01   PDF PDF file (119 KB) 

Food-Effect Bioavailability and Bioequivalence Studies
This document provides guidance to sponsors of new drug applications (NDAs), abbreviated new drug applications (ANDAs), and abbreviated antibiotic drug applications (AADAs) who intend to conduct food-effect bioavailability (BA) and bioequivalence (BE) studies for oral immediate release (IR) or modified release (MR) dosage forms. FDA

 1997-10-01   PDF PDF file (42 KB) 

SUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation
This guide provides recommendations to pharmaceutical sponsors of new drug applications (NDAs), abbreviated new drug applications (ANDAs), and abbreviated antibiotic drug applications (AADAs) who intend to change (1) the components or composition, (2) the site of manufacture, (3) the scale-up/scale-down of manufacture, and/or (4) the manufacturing (process and equipment) of a modified release solid oral dosage form during the post approval period. FDA

 1997-09-01   PDF PDF file (176 KB) 

Nonsterile Semisolid Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation
(NDAs), abbreviated new drug applications (ANDAs), and abbreviated antibiotic drug applications (AADAs) who intend to change (1) the components or composition, (2) the manufacturing (process and equipment), (3) the scale-up/scale-down of manufacture, and/or (4) the site of manufacture of a semisolid formulation during the post approval period. FDA

 1997-05-01   PDF PDF file (98 KB) 

Oral Extended (Controlled) Release Dosage Forms in Vivo Bioequivalence and in Vitro Dissolution Testing
This guide describes in vivo bioequivalence studies and in vitro dissolution testing recommended to applicants intending to submit Abbreviated New Drug Applications (ANDA's) for extended release products administered orally. FDA

    PDF PDF file (31 KB) 

Click here if you have not found what you were searching for.

21 CFR Part 11 Issues
Various aspects of electronic records and electronic signatures
Forum Database
Almost 100,000 searchable messages from 16 working newsgroups. Updated regularly.
Warning Letters Knowledge Base
An extremely versatile database that will assist familiarization with the regulatory requirements
Competency Trainings & Exams
Multimedia enriched learning materials, exercises and exams.
On-line Trainings & Exams
Web-based learning materials, exercises and exams

back Back
----------------------------------
--| What's New | Home | About Us | Contact Us | Help Center | Publications | Site Map | Links | Subscription |--
© 2001-2003 OPULUS® is licensed to BioMondex Ltd. All rights reserved. Please read the disclaimer.